Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-214676
Filing Date
2026-05-08
Accepted
2026-05-08 16:16:01
Documents
87
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q gyre-20260331.htm   iXBRL 10-Q 2840349
2 EX-31.1 gyre-ex31_1.htm EX-31.1 19994
3 EX-31.2 gyre-ex31_2.htm EX-31.2 19918
4 EX-32.1 gyre-ex32_1.htm EX-32.1 15753
5 EX-32.2 gyre-ex32_2.htm EX-32.2 15773
  Complete submission text file 0001193125-26-214676.txt   13486198

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT gyre-20260331.xsd EX-101.SCH 1849541
91 EXTRACTED XBRL INSTANCE DOCUMENT gyre-20260331_htm.xml XML 2856669
Mailing Address 12730 HIGH BLUFF DRIVE SUITE 250 SAN DIEGO CA 92130
Business Address 12730 HIGH BLUFF DRIVE SUITE 250 SAN DIEGO CA 92130 (858) 284-0115
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51173 | Film No.: 26958574
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)